During my formative years, a textbook of hematology would contain a single, rather brief, chapter on lymphomas. Within the pages would be clinical and pathologic descriptions in broad terms relating to a limited number of recognized histologic subtypes. As our knowledge increased, the chapters were separated into Hodgkin and non-Hodgkin, and then the latter into B- and T-cell. Treatment strategies from that period relied heavily on radiation therapy, but eventually active systemic treatment was available, although founded on those derivatives of mustard gas, the alkylating agents, as well as corticosteroids, and a series of other non-specific cytotoxic drugs. Means to assess response were rudimentary and variable, including radiographs, lymphangiograms and ultrasounds. It was totally unclear why some patients with a similar histologic morphology would be cured, whereas others were resistant to similar treatments. In this context, the glacial speed of journal publications was sufficient.
Editor-in-Chief: Bruce D. Cheson, MD, FACP, FAAS, FASCO
Professor of Medicine, Head of Hematology and Deputy Chief, Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, USA
Dr. Cheson attended the University of Virginia and then Tufts University Medical School. He completed his internship and residency in Internal Medicine at the University of Virginia Hospitals and then a clinical and research fellowship in Hematology at New England Medical Center Hospital. From 1977-1984 he was Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Utah. From 1986-2002, he was Head, Medicine Section, CTEP at the National Cancer Institute. Currently, Dr. Cheson is Professor of Medicine, Head of Hematology and Deputy Chief, Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center.